Abstract
Purpose: Patients with advanced cervical cancer have a very poor prognosis. The development of new drugs has led to an increase in the survival of these patients, although the situation can still be improved. In certain cases, despite the poor prognostic factors, the results can be very encouraging. Case description: We present the case of a 53-year-old patient with multiple sclerosis diagnosed with stage IV cervical carcinoma in June 2020. She received combined radiotherapy and chemotherapy, including carboplatin, paclitaxel, and bevacizumab, followed by maintenance therapy with bevacizumab. She achieved a complete response and after 36 months of maintenance with bevacizumab, she discontinued the drug maintaining the complete response.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
